Immuron Limited (ASX: IMC) is in pre-open this morning after the ASX granted the company a trading halt, pending a capital raising announcement.
Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans.
The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Wednesday 27th March 2013.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.